Across TCGA pan-cancer cohorts, LPA mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LPA data layer compared with 22 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LPA mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LPA expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, COAD, and HNSC are the cancer types where LPA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.319	0.625	<.001	73	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.874	.010	2	view →
LUAD	OS	Quartile	All	0.907	1.000	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: LPA tumor-vs-normal RNA expression · all LPA data types